Recently, a clinical trial evaluating dabrafenib (300 mg twice daily), trametinib (2 mg once daily), and pembrolizumab (2 mg/kg every 3 weeks) was conducted in 60 patients with BRAF V600E/K-mutated metastatic melanoma. The gene discussed is BRAF; the disease is metastatic melanoma.